MedTrace Logo

ALY688-SR in Generally Healthy Overweight or Obese Adults

NCT04855565 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-08-30

No results posted yet for this study

Summary

First in human study of ALY688-SR administered as a subcutaneous injection

Conditions

  • Overweight and Obesity

Interventions

DRUG

ALY688-SR

single dose subcutaneous injection

Sponsors & Collaborators

  • INC Research Australia Pty Ltd

    collaborator UNKNOWN

  • Allysta Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Ben Snyder, MD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-19
Primary Completion
2021-08-03
Completion
2021-08-03

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855565 on ClinicalTrials.gov